Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
05/2012
05/18/2012WO2012064845A2 G-csf polymer conjugates having a releasable linkage
05/18/2012WO2012064827A1 Methods and compositions to regulate plant transformation susceptibility
05/18/2012WO2012064659A1 Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
05/18/2012WO2012064429A2 Skin permeating and cell entering (space) peptides and methods of use thereof
05/18/2012WO2012063897A1 Modified fluorescent protein
05/18/2012WO2012063829A1 Novel gene, and osteoporosis testing method based on single nucleotide polymorphism on fong gene locus
05/18/2012WO2012063338A1 Protein having chitinase activity and uses thereof
05/18/2012WO2012063212A1 North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
05/18/2012WO2012063088A2 Collagen
05/18/2012WO2012063084A1 Bacterial methods
05/18/2012WO2012062873A2 Highly immunogenic hiv p24 sequences
05/18/2012WO2012062861A1 New adjuvant
05/18/2012WO2012062832A1 Microorganisms for 1,3-propanediol production using high glycerine concentration
05/18/2012WO2012062803A1 Double-acylated glp-1 derivatives
05/18/2012WO2012062228A2 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
05/18/2012WO2012062218A1 Soluble pd-1 variants, fusion constructs, and uses thereof
05/18/2012WO2012062078A1 N-terminal deletion variant of human fibroblast growth factor 21 and conjugate thereof
05/18/2012WO2012061937A1 Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
05/18/2012WO2012061910A2 Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis
05/18/2012WO2012061882A1 Treatment and prevention of malaria
05/18/2012WO2012037687A9 Therapeutic polypeptides and uses thereof
05/18/2012WO2012024283A3 Universal influenza a vaccines
05/18/2012WO2012024200A3 Novel bacillus thuringiensis gene with lepidopteran activity
05/18/2012WO2012022928A3 Gpcr as vaccines or for removing / inhibiting autoantibodies, toxins or ligands binding to the gpcr
05/18/2012WO2012020289A3 Specific active site inhibitors of enzymes or substrate binding partners and methods of producing same
05/18/2012WO2012018866A3 Methods and compositions for the diagnosis and treatment of breast cancer
05/18/2012WO2012012469A3 Signal biomarkers
05/18/2012WO2012011992A3 Ricin vaccine and methods of making and using thereof
05/18/2012WO2012003320A3 Flavivirus host-range mutations and uses thereof
05/18/2012WO2011161699A3 Immunosuppression modulating compounds
05/18/2012WO2011159895A3 Single chain insulin agonists exhibiting high activity at the insulin receptor
05/18/2012WO2011130666A3 Plants with altered cell wall biosynthesis and methods of use
05/18/2012WO2011060552A9 Variegation in plants
05/18/2012CA2817709A1 Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
05/18/2012CA2817568A1 Cancer therapies and diagnostics
05/18/2012CA2817486A1 North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
05/18/2012CA2817421A1 New adjuvant
05/18/2012CA2817418A1 Highly immunogenic hiv p24 sequences
05/18/2012CA2817373A1 Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
05/18/2012CA2817197A1 Fusion proteins comprising an engineered knottin peptide and uses thereof
05/18/2012CA2816722A1 Conjugates of an il-2 moiety and a polymer
05/18/2012CA2814814A1 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
05/18/2012CA2814441A1 Microorganisms for 1,3-propanediol production using high glycerine concentration
05/18/2012CA2811113A1 Skin permeating and cell entering (space) peptides and methods of use thereof
05/17/2012US20120124700 Maize Ethylene Signaling Genes and Modulation of Same for Improved Stress Tolerance in Plants
05/17/2012US20120124689 Plants and seeds of hybrid corn variety ch411439
05/17/2012US20120124684 Compositions and methods using alpha beta-crystallin in protecting the myocardium from ischemia/reperfusion injury
05/17/2012US20120124683 Delivery method
05/17/2012US20120123186 Therapeutic regimen for treating cancer
05/17/2012US20120123097 Ricin a chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin
05/17/2012US20120123096 Therapeutic nucleic acid-3'-conjugates
05/17/2012US20120123095 Process and system for obtaining botulinum neurotoxin
05/17/2012US20120123093 Novel surface antigen
05/17/2012US20120123092 Human a2a adenosine receptor crystals and uses thereof
05/17/2012US20120123090 Novel tumor antigen protein sart-3 and tumor antigen peptides thereof
05/17/2012US20120123089 Preparative non-linear gradient based chromatographic method and purified products thereof
05/17/2012US20120122960 Organic Compositions to Treat Beta-ENaC-Related Diseases
05/17/2012US20120122800 Long-Acting DNA Dendrimers and Methods Thereof
05/17/2012US20120122791 Substrate for cartilage cultivation using artificial collagen, and method for cartilage regeneration treatment using the substrate
05/17/2012US20120122788 E-polylysine conjugates and the use thereof
05/17/2012US20120122783 Glucagon antagonists
05/17/2012US20120122778 Modified TGF-beta superfamily protein
05/17/2012US20120122766 Novel Polypeptide Having Angiogenesis-Inducing Activity And Antibacterial Activity, And Use Thereof For Medical Purposes
05/17/2012US20120122765 Compounds and related methods for manipulating parp-1-dependent cell death
05/17/2012US20120122762 186 Human Secreted Proteins
05/17/2012US20120122761 Methods for detecting a polymorphism in the nfkb1 gene promoter
05/17/2012US20120122238 VMP-Like Sequences of Pathogenic Borrelia
05/17/2012US20120122221 Culture medium and hydrophilic composite thereof
05/17/2012US20120122210 Carrier peptide fragment and use thereof
05/17/2012US20120122181 Method for determining antagonist activity to a cytokinin receptor
05/17/2012US20120122179 Means for purifying a protein of blood plasma and methods for implementing same
05/17/2012US20120122133 Novel devices for the detection of the presence and/or activity of proteases in biological samples
05/17/2012US20120122124 New bacteriophage adhesion proteins
05/17/2012US20120122119 Methods of identifying compounds that bind to a toll-like receptor
05/17/2012US20120122107 Homeostatic multidomain protein, and uses for it
05/17/2012US20120122076 Purification of antibodies using simulated moving bed chromatography
05/17/2012US20120121709 Phase transition biopolymers and methods of use
05/17/2012US20120121641 Mhc oligomer and method of making the same
05/17/2012US20120121639 Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species
05/17/2012US20120121635 Expression in plants of HIV-related proteins
05/17/2012US20120121634 Soluble pd-1 variants, fusion constructs, and uses thereof
05/17/2012US20120121633 Hiv cd4 binding site based covalent immunogen compositions
05/17/2012US20120121631 Polyvalent vaccine
05/17/2012US20120121630 Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast
05/17/2012US20120121628 Lipidated polyepitope vaccines
05/17/2012US20120121627 Peptides for active anti-cytokine immunization
05/17/2012US20120121626 Chimeric VEGF Peptides
05/17/2012US20120121623 Novel antipathogenic peptides
05/17/2012US20120121606 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
05/17/2012US20120121602 Novel proteins
05/17/2012US20120121601 Mammalian receptor proteins; related reagents and methods
05/17/2012US20120121591 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
05/17/2012US20120121590 Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein (gal-3bp, btbd17b, mac-2 binding protein)
05/17/2012US20120121589 Modified egfr ectodomain
05/17/2012US20120121577 Antibodies as t cell receptor mimics, methods of production and uses thereof
05/17/2012US20120121542 Red-shifted opsin molecules and uses thereof
05/17/2012US20120121537 Methods and Compositions for Inhibiting Hepatitis C Virus Replication
05/17/2012US20120121501 Hmgn2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
05/17/2012US20120117867 Plants with Increased Yield
05/16/2012EP2453019A1 Gene therapy compositions for preventing and/or treating autoimmune diseases
1 ... 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 ... 2916